Prediagnostic levels of C‐peptide, IGF‐I, IGFBP ‐1, ‐2 and ‐3 and risk of endometrial cancer
Conditions related to chronic hyperinsulinemia, such as obesity, noninsulin dependent diabetes mellitus and polycystic ovary syndrome, are associated with an increased risk of endometrial cancer. Elevated plasma IGF‐I and decreased levels of IGF‐binding proteins have been shown to be associated with...
Saved in:
Published in | International journal of cancer Vol. 108; no. 2; pp. 262 - 268 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Hoboken
Wiley Subscription Services, Inc., A Wiley Company
10.01.2004
Wiley-Liss |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Conditions related to chronic hyperinsulinemia, such as obesity, noninsulin dependent diabetes mellitus and polycystic ovary syndrome, are associated with an increased risk of endometrial cancer. Elevated plasma IGF‐I and decreased levels of IGF‐binding proteins have been shown to be associated with increased risk of several cancer types that are frequent in affluent societies. We investigated for the first time in a prospective study the association of pre‐diagnostic blood concentrations of C‐peptide (a marker of pancreatic insulin production), IGF‐I, IGFBP‐1, ‐2 and ‐3 with endometrial cancer risk. A case‐control study was nested within 3 cohorts in New York (USA), Umeå (Sweden) and Milan (Italy). It included 166 women with primary invasive endometrial cancer and 315 matched controls, of which 44 case and 78 control subjects were premenopausal at recruitment. Endometrial cancer risk increased with increasing levels of C‐peptide (ptrend = 0.0002), up to an odds ratio (OR) of 4.76 [95% confidence interval (CI) = 1.91–11.8] for the highest quintile. This association remained after adjustment for BMI and other confounders [OR for the top quintile = 4.40 (1.65–11.7)]. IGFBP‐1 levels were inversely related to endometrial cancer [ptrend = 0.002; OR in the upper quintile = 0.30 (0.15–0.62)], but the association was weakened and lost statistical significance after adjustment for confounders [ptrend = 0.06; OR in the upper quintile = 0.49 (0.22–1.07)]. Risk was unrelated to levels of IGF‐I, IGFBP‐2 and IGFBP‐3. Chronic hyperinsulinemia, as reflected by increased circulating C‐peptide, is associated with increased endometrial cancer risk. Decrease in the prevalence of chronic hyperinsulinemia, through changes in lifestyle or medication, is expected to prevent endometrial cancer. © 2003 Wiley‐Liss, Inc. |
---|---|
AbstractList | Conditions related to chronic hyperinsulinemia, such as obesity, noninsulin dependent diabetes mellitus and polycystic ovary syndrome, are associated with an increased risk of endometrial cancer. Elevated plasma IGF-I and decreased levels of IGF-binding proteins have been shown to be associated with increased risk of several cancer types that are frequent in affluent societies. We investigated for the first time in a prospective study the association of pre-diagnostic blood concentrations of C-peptide (a marker of pancreatic insulin production), IGF-I, IGFBP-1, -2 and -3 with endometrial cancer risk. A case-control study was nested within 3 cohorts in New York (USA), Umeå (Sweden) and Milan (Italy). It included 166 women with primary invasive endometrial cancer and 315 matched controls, of which 44 case and 78 control subjects were premenopausal at recruitment. Endometrial cancer risk increased with increasing levels of C-peptide ( p trend = 0.0002), up to an odds ratio (OR) of 4.76 [95% confidence interval (CI) = 1.91-11.8] for the highest quintile. This association remained after adjustment for BMI and other confounders [OR for the top quintile = 4.40 (1.65-11.7)]. IGFBP-1 levels were inversely related to endometrial cancer [ p trend = 0.002; OR in the upper quintile = 0.30 (0.15-0.62)], but the association was weakened and lost statistical significance after adjustment for confounders [ p trend = 0.06; OR in the upper quintile = 0.49 (0.22-1.07)]. Risk was unrelated to levels of IGF-I, IGFBP-2 and IGFBP-3. Chronic hyperinsulinemia, as reflected by increased circulating C-peptide, is associated with increased endometrial cancer risk. Decrease in the prevalence of chronic hyperinsulinemia, through changes in lifestyle or medication, is expected to prevent endometrial cancer. Conditions related to chronic hyperinsulinemia, such as obesity, noninsulin dependent diabetes mellitus and polycystic ovary syndrome, are associated with an increased risk of endometrial cancer. Elevated plasma IGF‐I and decreased levels of IGF‐binding proteins have been shown to be associated with increased risk of several cancer types that are frequent in affluent societies. We investigated for the first time in a prospective study the association of pre‐diagnostic blood concentrations of C‐peptide (a marker of pancreatic insulin production), IGF‐I, IGFBP‐1, ‐2 and ‐3 with endometrial cancer risk. A case‐control study was nested within 3 cohorts in New York (USA), Umeå (Sweden) and Milan (Italy). It included 166 women with primary invasive endometrial cancer and 315 matched controls, of which 44 case and 78 control subjects were premenopausal at recruitment. Endometrial cancer risk increased with increasing levels of C‐peptide (ptrend = 0.0002), up to an odds ratio (OR) of 4.76 [95% confidence interval (CI) = 1.91–11.8] for the highest quintile. This association remained after adjustment for BMI and other confounders [OR for the top quintile = 4.40 (1.65–11.7)]. IGFBP‐1 levels were inversely related to endometrial cancer [ptrend = 0.002; OR in the upper quintile = 0.30 (0.15–0.62)], but the association was weakened and lost statistical significance after adjustment for confounders [ptrend = 0.06; OR in the upper quintile = 0.49 (0.22–1.07)]. Risk was unrelated to levels of IGF‐I, IGFBP‐2 and IGFBP‐3. Chronic hyperinsulinemia, as reflected by increased circulating C‐peptide, is associated with increased endometrial cancer risk. Decrease in the prevalence of chronic hyperinsulinemia, through changes in lifestyle or medication, is expected to prevent endometrial cancer. © 2003 Wiley‐Liss, Inc. Conditions related to chronic hyperinsulinemia, such as obesity, noninsulin dependent diabetes mellitus and polycystic ovary syndrome, are associated with an increased risk of endometrial cancer. Elevated plasma IGF-I and decreased levels of IGF-binding proteins have been shown to be associated with increased risk of several cancer types that are frequent in affluent societies. We investigated for the first time in a prospective study the association of pre-diagnostic blood concentrations of C-peptide (a marker of pancreatic insulin production), IGF-I, IGFBP-1, -2 and -3 with endometrial cancer risk. A case-control study was nested within 3 cohorts in New York (USA), Umeå (Sweden) and Milan (Italy). It included 166 women with primary invasive endometrial cancer and 315 matched controls, of which 44 case and 78 control subjects were premenopausal at recruitment. Endometrial cancer risk increased with increasing levels of C-peptide (ptrend = 0.0002), up to an odds ratio (OR) of 4.76 [95% confidence interval (CI) = 1.91-11.8] for the highest quintile. This association remained after adjustment for BMI and other confounders [OR for the top quintile = 4.40 (1.65-11.7)]. IGFBP-1 levels were inversely related to endometrial cancer [ptrend = 0.002; OR in the upper quintile = 0.30 (0.15-0.62)], but the association was weakened and lost statistical significance after adjustment for confounders [ptrend = 0.06; OR in the upper quintile = 0.49 (0.22-1.07)]. Risk was unrelated to levels of IGF-I, IGFBP-2 and IGFBP-3. Chronic hyperinsulinemia, as reflected by increased circulating C-peptide, is associated with increased endometrial cancer risk. Decrease in the prevalence of chronic hyperinsulinemia, through changes in lifestyle or medication, is expected to prevent endometrial cancer. Conditions related to chronic hyperinsulinemia, such as obesity, noninsulin dependent diabetes mellitus and polycystic ovary syndrome, are associated with an increased risk of endometrial cancer. Elevated plasma IGF-I and decreased levels of IGF-binding proteins have been shown to be associated with increased risk of several cancer types that are frequent in affluent societies. We investigated for the first time in a prospective study the association of pre-diagnostic blood concentrations of C-peptide (a marker of pancreatic insulin production), IGF-I, IGFBP-1, -2 and -3 with endometrial cancer risk. A case-control study was nested within 3 cohorts in New York (USA), Umeå (Sweden) and Milan (Italy). It included 166 women with primary invasive endometrial cancer and 315 matched controls, of which 44 case and 78 control subjects were premenopausal at recruitment. Endometrial cancer risk increased with increasing levels of C-peptide (ptrend = 0.0002), up to an odds ratio (OR) of 4.76 [95% confidence interval (CI) = 1.91-11.8] for the highest quintile. This association remained after adjustment for BMI and other confounders [OR for the top quintile = 4.40 (1.65-11.7)]. IGFBP-1 levels were inversely related to endometrial cancer [ptrend = 0.002; OR in the upper quintile = 0.30 (0.15-0.62)], but the association was weakened and lost statistical significance after adjustment for confounders [ptrend = 0.06; OR in the upper quintile = 0.49 (0.22-1.07)]. Risk was unrelated to levels of IGF-I, IGFBP-2 and IGFBP-3. Chronic hyperinsulinemia, as reflected by increased circulating C-peptide, is associated with increased endometrial cancer risk. Decrease in the prevalence of chronic hyperinsulinemia, through changes in lifestyle or medication, is expected to prevent endometrial cancer.Conditions related to chronic hyperinsulinemia, such as obesity, noninsulin dependent diabetes mellitus and polycystic ovary syndrome, are associated with an increased risk of endometrial cancer. Elevated plasma IGF-I and decreased levels of IGF-binding proteins have been shown to be associated with increased risk of several cancer types that are frequent in affluent societies. We investigated for the first time in a prospective study the association of pre-diagnostic blood concentrations of C-peptide (a marker of pancreatic insulin production), IGF-I, IGFBP-1, -2 and -3 with endometrial cancer risk. A case-control study was nested within 3 cohorts in New York (USA), Umeå (Sweden) and Milan (Italy). It included 166 women with primary invasive endometrial cancer and 315 matched controls, of which 44 case and 78 control subjects were premenopausal at recruitment. Endometrial cancer risk increased with increasing levels of C-peptide (ptrend = 0.0002), up to an odds ratio (OR) of 4.76 [95% confidence interval (CI) = 1.91-11.8] for the highest quintile. This association remained after adjustment for BMI and other confounders [OR for the top quintile = 4.40 (1.65-11.7)]. IGFBP-1 levels were inversely related to endometrial cancer [ptrend = 0.002; OR in the upper quintile = 0.30 (0.15-0.62)], but the association was weakened and lost statistical significance after adjustment for confounders [ptrend = 0.06; OR in the upper quintile = 0.49 (0.22-1.07)]. Risk was unrelated to levels of IGF-I, IGFBP-2 and IGFBP-3. Chronic hyperinsulinemia, as reflected by increased circulating C-peptide, is associated with increased endometrial cancer risk. Decrease in the prevalence of chronic hyperinsulinemia, through changes in lifestyle or medication, is expected to prevent endometrial cancer. Conditions related to chronic hyperinsulinemia, such as obesity, noninsulin dependent diabetes mellitus and polycystic ovary syndrome, are associated with an increased risk of endometrial cancer. Elevated plasma IGF‐I and decreased levels of IGF‐binding proteins have been shown to be associated with increased risk of several cancer types that are frequent in affluent societies. We investigated for the first time in a prospective study the association of pre‐diagnostic blood concentrations of C‐peptide (a marker of pancreatic insulin production), IGF‐I, IGFBP‐1, ‐2 and ‐3 with endometrial cancer risk. A case‐control study was nested within 3 cohorts in New York (USA), Umeå (Sweden) and Milan (Italy). It included 166 women with primary invasive endometrial cancer and 315 matched controls, of which 44 case and 78 control subjects were premenopausal at recruitment. Endometrial cancer risk increased with increasing levels of C‐peptide ( p trend = 0.0002), up to an odds ratio (OR) of 4.76 [95% confidence interval (CI) = 1.91–11.8] for the highest quintile. This association remained after adjustment for BMI and other confounders [OR for the top quintile = 4.40 (1.65–11.7)]. IGFBP‐1 levels were inversely related to endometrial cancer [ p trend = 0.002; OR in the upper quintile = 0.30 (0.15–0.62)], but the association was weakened and lost statistical significance after adjustment for confounders [ p trend = 0.06; OR in the upper quintile = 0.49 (0.22–1.07)]. Risk was unrelated to levels of IGF‐I, IGFBP‐2 and IGFBP‐3. Chronic hyperinsulinemia, as reflected by increased circulating C‐peptide, is associated with increased endometrial cancer risk. Decrease in the prevalence of chronic hyperinsulinemia, through changes in lifestyle or medication, is expected to prevent endometrial cancer. © 2003 Wiley‐Liss, Inc. |
Author | Lenner, Per Lukanova, Annekatrin Koenig, Karen L. Toniolo, Paolo Riboli, Elio Lundin, Eva Biessy, Carine Hallmans, Göran Zeleniuch‐Jacquotte, Anne Shore, Roy E. Berrino, Franco Micheli, Andrea Rinaldi, Sabina Muti, Paola Arslan, Alan A. Kaaks, Rudolf Krogh, Vittorio Stattin, Par |
Author_xml | – sequence: 1 givenname: Annekatrin surname: Lukanova fullname: Lukanova, Annekatrin – sequence: 2 givenname: Anne surname: Zeleniuch‐Jacquotte fullname: Zeleniuch‐Jacquotte, Anne – sequence: 3 givenname: Eva surname: Lundin fullname: Lundin, Eva – sequence: 4 givenname: Andrea surname: Micheli fullname: Micheli, Andrea – sequence: 5 givenname: Alan A. surname: Arslan fullname: Arslan, Alan A. – sequence: 6 givenname: Sabina surname: Rinaldi fullname: Rinaldi, Sabina – sequence: 7 givenname: Paola surname: Muti fullname: Muti, Paola – sequence: 8 givenname: Per surname: Lenner fullname: Lenner, Per – sequence: 9 givenname: Karen L. surname: Koenig fullname: Koenig, Karen L. – sequence: 10 givenname: Carine surname: Biessy fullname: Biessy, Carine – sequence: 11 givenname: Vittorio surname: Krogh fullname: Krogh, Vittorio – sequence: 12 givenname: Elio surname: Riboli fullname: Riboli, Elio – sequence: 13 givenname: Roy E. surname: Shore fullname: Shore, Roy E. – sequence: 14 givenname: Par surname: Stattin fullname: Stattin, Par – sequence: 15 givenname: Franco surname: Berrino fullname: Berrino, Franco – sequence: 16 givenname: Göran surname: Hallmans fullname: Hallmans, Göran – sequence: 17 givenname: Paolo surname: Toniolo fullname: Toniolo, Paolo – sequence: 18 givenname: Rudolf surname: Kaaks fullname: Kaaks, Rudolf email: kaaks@iarc.fr |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=15441687$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/14639613$$D View this record in MEDLINE/PubMed https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-15439$$DView record from Swedish Publication Index |
BookMark | eNp1kc1u1DAUhS1URKcDC14AZQNSpUlrx44zWZaBlkGV6ALYWjf2TeXixKmdUHXXR-AZeRI8PxQJwcY-lr9zpHvPETnofY-EvGT0hFFanNobfcJYKcQTMmO0rnJasPKAzNIfzSvG5SE5ivGG0gRR8YwcMiF5LRmfkfYqoLFw3fs4Wp05_I4uZr7NVj8ffgw4jNbgIltfnKfneiveXmVJs8XmLDLozUbwrQg2ftt4sTe-wzFYcJmGXmN4Tp624CK-2N9z8uX8_efVh_zy08V6dXaZa0GFyMtyKRFaLQpZlBKMqRrDmqYQmtZooFlSbSppOAfKC97KGkowknKUBQPgSz4ni11uvMNhatQQbAfhXnmw6p39eqZ8uFZTN6m0LV4n_M0OH4K_nTCOqrNRo3PQo5-iqlhZUZoWNSev9uDUdGgec38vMgGv9wBEDa4NaWwb_3CpHCaXVeJOd5wOPsaArdJ2hNH6fgxgnWJUbSpVqVK1rTQ5jv9yPIb-g92n31mH9_8H1frjauf4BSYVsRY |
CODEN | IJCNAW |
CitedBy_id | crossref_primary_10_1016_j_ijrobp_2016_02_048 crossref_primary_10_1016_j_ecl_2012_04_014 crossref_primary_10_1158_1055_9965_EPI_15_1145 crossref_primary_10_1038_nrc1387 crossref_primary_10_1016_j_ajog_2011_05_042 crossref_primary_10_1007_s00223_020_00780_6 crossref_primary_10_1186_1471_2407_14_728 crossref_primary_10_1080_13813450902878054 crossref_primary_10_1158_1055_9965_EPI_06_1062 crossref_primary_10_1152_physrev_00030_2014 crossref_primary_10_1093_aje_kws309 crossref_primary_10_1038_s41598_024_73429_1 crossref_primary_10_1093_aje_kwq006 crossref_primary_10_1002_ijc_22676 crossref_primary_10_1016_j_ygyno_2012_03_012 crossref_primary_10_1158_1055_9965_EPI_06_0775 crossref_primary_10_1038_s41598_017_04526_7 crossref_primary_10_1002_ijc_21354 crossref_primary_10_1093_ajcn_nqac229 crossref_primary_10_1158_1055_9965_EPI_14_0157 crossref_primary_10_3945_ajcn_112_039537 crossref_primary_10_1210_jc_2012_1490 crossref_primary_10_3390_jcm14030751 crossref_primary_10_1038_nrc1408 crossref_primary_10_1080_13813450801954303 crossref_primary_10_1016_j_ygyno_2020_05_033 crossref_primary_10_1158_1055_9965_EPI_11_0766 crossref_primary_10_1002_ijc_27622 crossref_primary_10_1111_jog_14155 crossref_primary_10_1007_s12020_013_9973_3 crossref_primary_10_1158_1055_9965_EPI_10_0832 crossref_primary_10_1007_s00125_007_0681_5 crossref_primary_10_3109_09513590_2012_752452 crossref_primary_10_1016_j_ygyno_2012_03_032 crossref_primary_10_1158_0008_5472_CAN_07_0373 crossref_primary_10_1111_j_1368_504X_2004_00328_x crossref_primary_10_1002_ijc_22578 crossref_primary_10_1007_s12094_015_1309_8 crossref_primary_10_1158_1055_9965_EPI_11_1105 crossref_primary_10_1080_01635581_2018_1460681 crossref_primary_10_1007_s12672_010_0013_y crossref_primary_10_1017_S0029665108006976 crossref_primary_10_1007_s10552_013_0314_x crossref_primary_10_1158_1055_9965_EPI_07_2686 crossref_primary_10_1158_1055_9965_EPI_07_2567 crossref_primary_10_1002_ijc_24927 crossref_primary_10_1158_1055_9965_EPI_06_0960 crossref_primary_10_1210_jc_2006_1371 crossref_primary_10_1007_s43032_020_00423_z crossref_primary_10_1007_s00125_020_05228_y crossref_primary_10_1200_JCO_2012_48_2596 crossref_primary_10_12688_wellcomeopenres_16417_1 crossref_primary_10_1007_s13668_014_0112_4 crossref_primary_10_1079_PHN2005741 crossref_primary_10_1016_j_cgh_2006_06_022 crossref_primary_10_1007_s10552_006_0094_7 crossref_primary_10_1158_1078_0432_CCR_16_3011 crossref_primary_10_1007_s00005_011_0119_0 crossref_primary_10_1136_bmjopen_2015_008541 crossref_primary_10_1007_s10552_012_9971_4 crossref_primary_10_1016_j_dsx_2009_08_002 crossref_primary_10_1038_bjc_2012_19 crossref_primary_10_18632_oncotarget_28513 crossref_primary_10_3389_fcell_2022_800181 crossref_primary_10_1158_1055_9965_607_13_4 crossref_primary_10_1007_s00432_022_04288_4 crossref_primary_10_1158_1940_6207_CAPR_16_0224 crossref_primary_10_1080_13813450801969715 crossref_primary_10_1016_j_canlet_2011_11_011 crossref_primary_10_1007_s00432_004_0587_2 crossref_primary_10_1080_13813450801954451 crossref_primary_10_1530_ERC_12_0229 crossref_primary_10_3390_cancers12092559 crossref_primary_10_1002_ijc_28589 crossref_primary_10_1007_s10552_016_0751_4 crossref_primary_10_1038_sj_bjc_6604496 crossref_primary_10_1080_01635580701328073 crossref_primary_10_1038_sj_bjc_6603200 crossref_primary_10_1200_JCO_2010_27_9935 crossref_primary_10_1016_j_ejca_2015_08_031 crossref_primary_10_1111_cas_16447 crossref_primary_10_1586_17474108_1_1_81 crossref_primary_10_3892_ol_2018_9409 crossref_primary_10_1016_j_ygyno_2007_08_002 crossref_primary_10_1158_1055_9965_EPI_06_0465 crossref_primary_10_1590_S0004_27302009000200013 crossref_primary_10_1158_1055_9965_98_14_1 crossref_primary_10_1038_bjc_2013_61 crossref_primary_10_1007_s10620_015_3873_8 crossref_primary_10_1038_s41416_021_01518_3 crossref_primary_10_1158_1055_9965_EPI_06_0625 crossref_primary_10_1016_j_soard_2017_01_042 crossref_primary_10_1080_00016340802160079 crossref_primary_10_1155_2013_632461 crossref_primary_10_3390_cancers13092149 crossref_primary_10_3892_ijo_2015_2865 crossref_primary_10_1016_j_heliyon_2023_e16470 crossref_primary_10_1007_s10911_008_9104_6 crossref_primary_10_1016_j_beem_2008_08_003 crossref_primary_10_1080_09513590400021201 crossref_primary_10_1158_1055_9965_EPI_20_0965 crossref_primary_10_1371_journal_pone_0129824 crossref_primary_10_1002_cncr_28853 crossref_primary_10_1158_1055_9965_195_14_1 crossref_primary_10_1158_1055_9965_EPI_06_0751 crossref_primary_10_1016_j_ejogrb_2016_06_013 crossref_primary_10_1042_CS20090399 crossref_primary_10_1016_j_ygyno_2016_01_020 crossref_primary_10_1002_ijc_23900 crossref_primary_10_3390_nu12010114 crossref_primary_10_1002_ijc_22140 crossref_primary_10_1007_s12328_010_0177_6 crossref_primary_10_1016_j_soard_2014_08_012 crossref_primary_10_1186_s12885_017_3068_0 crossref_primary_10_1158_0008_5472_CAN_20_1281 crossref_primary_10_3389_fnut_2023_1291355 crossref_primary_10_3390_cancers17010129 crossref_primary_10_1093_aje_kwm161 crossref_primary_10_1007_s00394_012_0376_7 crossref_primary_10_1586_17446651_2016_1128325 crossref_primary_10_1016_j_semcancer_2024_01_003 crossref_primary_10_1002_ijc_22422 crossref_primary_10_1093_annonc_mdv142 crossref_primary_10_1002_ijc_24722 crossref_primary_10_1016_j_ygyno_2009_12_029 |
Cites_doi | 10.1136/gut.50.5.642 10.1023/A:1022518321634 10.1016/S0002-9378(98)70244-3 10.1002/sim.935 10.1159/000299079 10.1210/jc.76.5.1115 10.1097/00001648-200011000-00004 10.1210/edrv.21.3.0399 10.1002/ijc.2910590303 10.2307/2347069 10.1080/1464727002000198781 10.1002/(SICI)1097-0215(19970502)71:3<360::AID-IJC9>3.0.CO;2-W 10.3109/09513599809012842 10.1210/jc.75.5.1235 10.1006/gyno.1993.1134 10.1016/0378-5122(95)00935-E 10.1093/jnci/92.19.1592 10.1038/bjc.1988.44 10.1093/oxfordjournals.aje.a009065 10.1210/edrv-11-3-443 10.1111/j.1749-6632.1991.tb37856.x 10.1210/jcem-67-1-144 10.1016/S0083-6729(08)60444-6 10.1002/1097-0142(194911)2:6<957::AID-CNCR2820020604>3.0.CO;2-6 10.1210/er.16.1.3 10.1079/PNS200070 10.1006/gyno.1998.5089 10.1210/jc.77.1.199 10.1023/A:1016392129279 10.1002/1097-0215(200002)9999:9999<::AID-IJC1053>3.0.CO;2-T 10.1093/oxfordjournals.aje.a009301 10.1023/A:1013708627664 10.1002/1097-0215(20001201)88:5<828::AID-IJC22>3.0.CO;2-8 |
ContentType | Journal Article |
Copyright | Copyright © 2003 Wiley‐Liss, Inc. 2004 INIST-CNRS Copyright 2003 Wiley-Liss, Inc. |
Copyright_xml | – notice: Copyright © 2003 Wiley‐Liss, Inc. – notice: 2004 INIST-CNRS – notice: Copyright 2003 Wiley-Liss, Inc. |
DBID | AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7X8 ADTPV AOWAS D93 |
DOI | 10.1002/ijc.11544 |
DatabaseName | CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic SwePub SwePub Articles SWEPUB Umeå universitet |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic CrossRef |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1097-0215 |
EndPage | 268 |
ExternalDocumentID | oai_DiVA_org_umu_15439 14639613 15441687 10_1002_ijc_11544 IJC11544 |
Genre | article Multicenter Study Research Support, U.S. Gov't, P.H.S Comparative Study Research Support, Non-U.S. Gov't Journal Article |
GeographicLocations | Italy Sweden United States North America Europe America |
GrantInformation_xml | – fundername: US National Cancer Institute funderid: R01 CA81188‐01; R01 CA81200‐01; R01 CA81212‐01; R01 CA34588 – fundername: NCI NIH HHS grantid: R01 CA81188-01 – fundername: NCI NIH HHS grantid: R01 CA81200-01 – fundername: NCI NIH HHS grantid: R01 CA34588 – fundername: NCI NIH HHS grantid: R01 CA81212-01 |
GroupedDBID | --- -~X .3N .55 .GA .Y3 05W 0R~ 10A 1L6 1OB 1OC 1ZS 24P 31~ 33P 3O- 3SF 3WU 4.4 4ZD 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AAHQN AAIPD AAMNL AANLZ AAONW AASGY AAXRX AAYCA AAZKR ABCQN ABCUV ABIJN ABJNI ABLJU ABOCM ABPVW ABQWH ABXGK ACAHQ ACCFJ ACCZN ACFBH ACGFO ACGFS ACGOF ACIWK ACMXC ACPOU ACPRK ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN ADZOD AEEZP AEGXH AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFFPM AFGKR AFPWT AFRAH AFWVQ AFZJQ AHBTC AHMBA AIACR AIAGR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ATUGU AZBYB AZVAB BAFTC BFHJK BHBCM BMXJE BROTX BRXPI BY8 CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DU5 EBS EJD EX3 F00 F01 F04 F5P FUBAC G-S G.N GNP GODZA H.X HBH HGLYW HHY HHZ HZ~ IH2 IX1 J0M JPC KBYEO KQQ L7B LATKE LAW LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ NNB O66 O9- OIG OK1 P2P P2W P2X P2Z P4B P4D PQQKQ Q.N Q11 QB0 QRW R.K RIWAO RJQFR ROL RWI RX1 SUPJJ UB1 UDS V2E V8K V9Y W2D W8V W99 WBKPD WHWMO WIB WIH WIJ WIK WIN WJL WOHZO WOW WQJ WRC WUP WVDHM WWO WXI WXSBR X7M XG1 XPP XV2 ZZTAW ~IA ~WT AAYXX AEYWJ AGYGG CITATION .GJ 8WZ A6W AAMMB AANHP ABEFU ABEML ACBWZ ACRPL ACSCC ACYXJ ADNMO AEFGJ AGHNM AGQPQ AGXDD AHEFC AI. AIDQK AIDYY ASPBG AVWKF AZFZN BDRZF C45 EMOBN FEDTE GLUZI HF~ HVGLF IQODW M6P OVD PALCI RYL SAMSI TEORI VH1 Y6R ZGI ZXP CGR CUY CVF ECM EIF NPM 7X8 ADTPV AOWAS D93 |
ID | FETCH-LOGICAL-c4044-5586eafc426256add7bd1bb24c09edab80cd76d33a0323f69a5ad603e621aa383 |
IEDL.DBID | DR2 |
ISSN | 0020-7136 1097-0215 |
IngestDate | Thu Aug 21 06:40:39 EDT 2025 Fri Jul 11 16:33:08 EDT 2025 Wed Feb 19 01:51:43 EST 2025 Mon Jul 21 09:12:04 EDT 2025 Tue Jul 01 04:26:19 EDT 2025 Thu Apr 24 23:12:47 EDT 2025 Wed Jan 22 16:39:06 EST 2025 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 2 |
Keywords | Human Endometrium cancer Peptides Malignant tumor Case control study Insulin like growth factor 1 Epidemiology C-Peptide Female genital diseases Polypeptide Insulin like growth factor binding protein 1 Cohort study Risk factor Uterine diseases Public health Growth factor |
Language | English |
License | http://onlinelibrary.wiley.com/termsAndConditions#vor CC BY 4.0 Copyright 2003 Wiley-Liss, Inc. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c4044-5586eafc426256add7bd1bb24c09edab80cd76d33a0323f69a5ad603e621aa383 |
Notes | The content of this report is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute. The NSHDS is sponsored by the Swedish Cancer Society and the ORDET cohort is sponsored by the Italian Association of Cancer Research. Fax +33‐4‐72‐73‐86‐31 ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 |
OpenAccessLink | https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ijc.11544 |
PMID | 14639613 |
PQID | 71570061 |
PQPubID | 23479 |
PageCount | 7 |
ParticipantIDs | swepub_primary_oai_DiVA_org_umu_15439 proquest_miscellaneous_71570061 pubmed_primary_14639613 pascalfrancis_primary_15441687 crossref_citationtrail_10_1002_ijc_11544 crossref_primary_10_1002_ijc_11544 wiley_primary_10_1002_ijc_11544_IJC11544 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 10 January 2004 |
PublicationDateYYYYMMDD | 2004-01-10 |
PublicationDate_xml | – month: 01 year: 2004 text: 10 January 2004 day: 10 |
PublicationDecade | 2000 |
PublicationPlace | Hoboken |
PublicationPlace_xml | – name: Hoboken – name: New York, NY – name: United States |
PublicationTitle | International journal of cancer |
PublicationTitleAlternate | Int J Cancer |
PublicationYear | 2004 |
Publisher | Wiley Subscription Services, Inc., A Wiley Company Wiley-Liss |
Publisher_xml | – name: Wiley Subscription Services, Inc., A Wiley Company – name: Wiley-Liss |
References | 2001; 91 1993; 47 1990; 11 1993; 49 1997; 44 1995; 16 2002; 50 2000; 3 2000; 21 2002; 6 2000; 88 1982; 31 2002; 13 1949; 2 2002; 11 2003; 14 2000; 92 1988; 57 1978; 38 1992; 75 1998; 179 2001; 20 1997; 146 1997; VII 2001; 60 1997; 71 1990 1993; 77 2000; 11 1993; 76 1995; 22 1997; 145 1988; 67 1984; 18 1998; 70 1994; 59 2001; 12 1991; 622 1998; 12 Gamayunova VB (e_1_2_6_12_2) 1997; 44 e_1_2_6_31_2 Kaaks R (e_1_2_6_5_2) 2002; 11 e_1_2_6_18_2 e_1_2_6_19_2 e_1_2_6_35_2 e_1_2_6_13_2 e_1_2_6_10_2 e_1_2_6_33_2 e_1_2_6_11_2 e_1_2_6_32_2 e_1_2_6_16_2 e_1_2_6_39_2 e_1_2_6_17_2 e_1_2_6_38_2 Parkin DM (e_1_2_6_2_2) 1997 e_1_2_6_14_2 e_1_2_6_37_2 e_1_2_6_15_2 e_1_2_6_36_2 Holmes MD (e_1_2_6_34_2) 2002; 11 e_1_2_6_20_2 Siiteri PK (e_1_2_6_30_2) 1978; 38 e_1_2_6_41_2 e_1_2_6_40_2 e_1_2_6_8_2 e_1_2_6_7_2 e_1_2_6_9_2 e_1_2_6_29_2 Vainio H (e_1_2_6_3_2) 2002 e_1_2_6_4_2 e_1_2_6_6_2 e_1_2_6_24_2 e_1_2_6_23_2 e_1_2_6_22_2 e_1_2_6_21_2 e_1_2_6_28_2 e_1_2_6_27_2 e_1_2_6_26_2 e_1_2_6_25_2 |
References_xml | – volume: 14 start-page: 65 year: 2003 end-page: 74 article-title: Lifestyle determinants of serum insulin‐like growth‐factor‐I (IGF‐I), C‐peptide and hormone binding protein levels in British women publication-title: Cancer Causes Control – volume: 75 start-page: 1235 year: 1992 end-page: 41 article-title: Steroid and peptide regulation of insulin‐like growth factor‐binding proteins secreted by human endometrial stromal cells is dependent on stromal differentiation publication-title: J Clin Endocrinol Metab – volume: 3 start-page: 101 year: 2000 end-page: 105 article-title: Long‐term consequences of polycystic ovary syndrome: results of a 31 year follow‐up study publication-title: Hum Fertil (Camb.) – volume: 2 start-page: 957 year: 1949 end-page: 63 article-title: Genesis of endometrial carcinoma. II. Cases 19 to 35 years old publication-title: Cancer – volume: 44 start-page: 123 year: 1997 end-page: 6 article-title: Comparative study of blood insulin levels in breast and endometrial cancer patients publication-title: Neoplasma – volume: 59 start-page: 307 year: 1994 end-page: 12 article-title: Suppressed expression of insulin‐like growth factor binding protein‐1 mRNA in the endometrium: a molecular mechanism associating endometrial cancer with its risk factors publication-title: Int J Cancer – volume: 12 start-page: 399 year: 1998 end-page: 406 article-title: Insulin‐like growth factors in endometrial function publication-title: Gynecol Endocrinol – volume: 6 year: 2002 – volume: 179 start-page: 6 year: 1998 end-page: 12 article-title: Specific binding and growth‐promoting activity of insulin in endometrial cancer cells in culture publication-title: Am J Obstet Gynecol – volume: 70 start-page: 202 year: 1998 end-page: 9 article-title: Transforming growth factor‐alpha and insulin‐like growth factor‐I, but not epidermal growth factor, elicit autocrine stimulation of mitogenesis in endometrial cancer cell lines publication-title: Gynecol Oncol – volume: 11 start-page: 862 year: 2002 end-page: 7 article-title: Lifestyle correlates of plasma insulin‐like growth factor I and insulin‐like growth factor binding protein 3 concentrations publication-title: Cancer Epidemiol Biomarkers Prev – year: 1990 – volume: 12 start-page: 951 year: 2001 end-page: 8 article-title: Determinants of circulating insulin‐like growth factor (IGF)‐I and IGF binding proteins 1‐3 in premenopausal women: physical activity and anthropometry (Netherlands) publication-title: Cancer Causes Control – volume: 77 start-page: 199 year: 1993 end-page: 204 article-title: Relationship between carbohydrate metabolism and serum insulin‐like growth factor system in postmenopausal women: comparison of endometrial cancer patients with healthy controls publication-title: J Clin Endocrinol Metab – volume: 71 start-page: 360 year: 1997 end-page: 3 article-title: Risk of endometrial and breast cancer in patients with diabetes mellitus publication-title: Int J Cancer – volume: 146 start-page: 476 year: 1997 end-page: 82 article-title: Insulin and endometrial cancer publication-title: Am J Epidemiol – volume: 60 start-page: 91 year: 2001 end-page: 106 article-title: Energy balance and cancer: the role of insulin and insulin‐like growth factor‐I publication-title: Proc Nutr Soc – volume: 22 start-page: 255 year: 1995 end-page: 62 article-title: Insulin‐like growth factor‐binding protein‐1: a biochemical marker of endometrial response to progestin during hormone replacement therapy publication-title: Maturitas – volume: 50 start-page: 642 year: 2002 end-page: 6 article-title: Plasma IGF‐I, IGF‐binding protein‐3 and risk of colorectal cancer: A prospective study in Northern Sweden publication-title: Gut – volume: 145 start-page: 970 year: 1997 end-page: 6 article-title: Epidemiology of insulin‐like growth factor‐I in elderly men and women: The Rancho Bernardo Study publication-title: Am J Epidemiol – volume: 16 start-page: 3 year: 1995 end-page: 34 article-title: Insulin‐like growth factors and their binding proteins: biological actions publication-title: Endocr Rev – volume: 11 start-page: 443 year: 1990 end-page: 53 article-title: Uterine insulin‐like growth factor‐1: regulation of expression and its role in estrogen‐induced uterine proliferation publication-title: Endocr Rev – volume: 57 start-page: 205 year: 1988 end-page: 12 article-title: The dose‐effect relationship between ‘unopposed’ oestrogens and endometrial mitotic rate: its central role in explaining and predicting endometrial cancer risk publication-title: Br J Cancer – volume: 21 start-page: 215 year: 2000 end-page: 44 article-title: The effects of insulin‐like growth factors on tumorigenesis and neoplastic growth publication-title: Endocr Rev – volume: 622 start-page: 120 year: 1991 end-page: 37 article-title: The insulin‐like growth factor binding proteins: the endometrium and decidua publication-title: Ann N Y Acad Sci – volume: 47 start-page: 1 year: 1993 end-page: 114 article-title: Insulin‐like growth factor binding proteins publication-title: Vitam Horm – volume: 11 start-page: 635 year: 2000 end-page: 40 article-title: Estrogen metabolism and risk of breast cancer: a prospective study of the 2:16alpha‐hydroxyestrone ratio in premenopausal and postmenopausal women publication-title: Epidemiology – volume: 13 start-page: 509 year: 2002 end-page: 16 article-title: Nonlinear relationship of insulin‐like growth factor (IGF)‐I and IGF‐I/IGF‐binding protein‐3 ratio with indices of adiposity and plasma insulin concentrations (Sweden) publication-title: Cancer Causes Control – volume: 92 start-page: 1592 year: 2000 end-page: 600 article-title: Serum C‐Peptide, Insulin‐Like Growth Factor (IGF)‐I, IGF‐Binding Proteins, and Colorectal Cancer Risk in Women publication-title: J Natl Cancer Inst – volume: 18 start-page: 190 year: 1984 end-page: 3 article-title: Increased rate of glucose intolerance in endometrial cancer: a community‐based study publication-title: Gynecol Obstet Invest – volume: 76 start-page: 1115 year: 1993 end-page: 22 article-title: Differential expression of messenger ribonucleic acids encoding insulin‐like growth factors and their receptors in human uterine endometrium and decidua publication-title: J Clin Endocrinol Metab – volume: 49 start-page: 325 year: 1993 end-page: 32 article-title: Mitogenic activity of growth factors in the human endometrial adenocarcinoma cell lines HEC‐1‐A and KLE publication-title: Gynecol Oncol – volume: VII year: 1997 – volume: 31 start-page: 9 year: 1982 end-page: 13 article-title: A generalization of the paired t‐test publication-title: Appl Statistics – volume: 11 start-page: 1531 year: 2002 end-page: 43 article-title: Obesity, endogenous hormones, and endometrial cancer risk; a synthetic review publication-title: Cancer Epidemiol Biomarkers Prev – volume: 88 start-page: 828 year: 2000 end-page: 32 article-title: Serum insulin‐like growth factor‐I and breast cancer publication-title: Int J Cancer – volume: 20 start-page: 3205 year: 2001 end-page: 14 article-title: Planning a reproducibility study: how many subjects and how many replicates per subject for an expected width of the 95 per cent confidence interval of the intraclass correlation coefficient publication-title: Stat Med – volume: 67 start-page: 144 year: 1988 end-page: 8 article-title: Hyperinsulinemia and stromal luteinization of the ovaries in postmenopausal women with endometrial cancer publication-title: J Clin Endocrinol Metab – volume: 91 start-page: 421 year: 2001 end-page: 30 article-title: Overweight as an avoidable cause of cancer in Europe publication-title: Int J Cancer – volume: 38 start-page: 4360 year: 1978 end-page: 6 article-title: Steroid hormones and endometrial cancer publication-title: Cancer Res – ident: e_1_2_6_26_2 doi: 10.1136/gut.50.5.642 – ident: e_1_2_6_36_2 doi: 10.1023/A:1022518321634 – ident: e_1_2_6_8_2 doi: 10.1016/S0002-9378(98)70244-3 – ident: e_1_2_6_29_2 doi: 10.1002/sim.935 – volume: 44 start-page: 123 year: 1997 ident: e_1_2_6_12_2 article-title: Comparative study of blood insulin levels in breast and endometrial cancer patients publication-title: Neoplasma – ident: e_1_2_6_13_2 doi: 10.1159/000299079 – ident: e_1_2_6_37_2 doi: 10.1210/jc.76.5.1115 – ident: e_1_2_6_25_2 doi: 10.1097/00001648-200011000-00004 – volume: 11 start-page: 862 year: 2002 ident: e_1_2_6_34_2 article-title: Lifestyle correlates of plasma insulin‐like growth factor I and insulin‐like growth factor binding protein 3 concentrations publication-title: Cancer Epidemiol Biomarkers Prev – ident: e_1_2_6_15_2 doi: 10.1210/edrv.21.3.0399 – ident: e_1_2_6_18_2 doi: 10.1002/ijc.2910590303 – ident: e_1_2_6_27_2 doi: 10.2307/2347069 – ident: e_1_2_6_7_2 doi: 10.1080/1464727002000198781 – ident: e_1_2_6_6_2 doi: 10.1002/(SICI)1097-0215(19970502)71:3<360::AID-IJC9>3.0.CO;2-W – ident: e_1_2_6_38_2 doi: 10.3109/09513599809012842 – ident: e_1_2_6_39_2 doi: 10.1210/jc.75.5.1235 – ident: e_1_2_6_40_2 doi: 10.1006/gyno.1993.1134 – year: 1997 ident: e_1_2_6_2_2 – ident: e_1_2_6_22_2 doi: 10.1016/0378-5122(95)00935-E – ident: e_1_2_6_32_2 doi: 10.1093/jnci/92.19.1592 – ident: e_1_2_6_21_2 doi: 10.1038/bjc.1988.44 – ident: e_1_2_6_31_2 doi: 10.1093/oxfordjournals.aje.a009065 – volume: 38 start-page: 4360 year: 1978 ident: e_1_2_6_30_2 article-title: Steroid hormones and endometrial cancer publication-title: Cancer Res – ident: e_1_2_6_17_2 doi: 10.1210/edrv-11-3-443 – ident: e_1_2_6_20_2 doi: 10.1111/j.1749-6632.1991.tb37856.x – ident: e_1_2_6_11_2 doi: 10.1210/jcem-67-1-144 – ident: e_1_2_6_23_2 doi: 10.1016/S0083-6729(08)60444-6 – ident: e_1_2_6_41_2 doi: 10.1002/1097-0142(194911)2:6<957::AID-CNCR2820020604>3.0.CO;2-6 – ident: e_1_2_6_19_2 doi: 10.1210/er.16.1.3 – ident: e_1_2_6_16_2 doi: 10.1079/PNS200070 – ident: e_1_2_6_28_2 – ident: e_1_2_6_14_2 doi: 10.1006/gyno.1998.5089 – volume: 11 start-page: 1531 year: 2002 ident: e_1_2_6_5_2 article-title: Obesity, endogenous hormones, and endometrial cancer risk; a synthetic review publication-title: Cancer Epidemiol Biomarkers Prev – ident: e_1_2_6_10_2 doi: 10.1210/jc.77.1.199 – ident: e_1_2_6_33_2 doi: 10.1023/A:1016392129279 – ident: e_1_2_6_4_2 doi: 10.1002/1097-0215(200002)9999:9999<::AID-IJC1053>3.0.CO;2-T – year: 2002 ident: e_1_2_6_3_2 – ident: e_1_2_6_9_2 doi: 10.1093/oxfordjournals.aje.a009301 – ident: e_1_2_6_35_2 doi: 10.1023/A:1013708627664 – ident: e_1_2_6_24_2 doi: 10.1002/1097-0215(20001201)88:5<828::AID-IJC22>3.0.CO;2-8 |
SSID | ssj0011504 |
Score | 2.1789336 |
Snippet | Conditions related to chronic hyperinsulinemia, such as obesity, noninsulin dependent diabetes mellitus and polycystic ovary syndrome, are associated with an... |
SourceID | swepub proquest pubmed pascalfrancis crossref wiley |
SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 262 |
SubjectTerms | Adult Aged Biological and medical sciences Biomarkers, Tumor - blood C-peptide C-Peptide - blood Case-Control Studies Chronic Disease Cohort Studies cohort study endometrial cancer Endometrial Neoplasms - blood Endometrial Neoplasms - diagnosis Female Female genital diseases Gynecology. Andrology. Obstetrics Humans Hyperinsulinism - blood Insulin - metabolism Insulin-Like Growth Factor Binding Protein 1 - blood Insulin-Like Growth Factor Binding Protein 2 - blood Insulin-Like Growth Factor Binding Protein 3 - blood insulin-like growth factor binding proteins Insulin-Like Growth Factor I - metabolism insulin-like growth factor-I Medical sciences MEDICIN MEDICINE Middle Aged Prognosis Prospective Studies Risk Factors Tumors |
Title | Prediagnostic levels of C‐peptide, IGF‐I, IGFBP ‐1, ‐2 and ‐3 and risk of endometrial cancer |
URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fijc.11544 https://www.ncbi.nlm.nih.gov/pubmed/14639613 https://www.proquest.com/docview/71570061 https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-15439 |
Volume | 108 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELaqHhASAsozQIuFQOLQbJ2Xk4hTu2XpViqqEEU9IFmOH6jQJqvdzYUTP4HfyC9hxk6yWlQkxCWaKGMltmfsz_H4G0JeRorBJFvI0OokDtOy0DAOIm1lDsZkLS8id1zs5D0_OkuPz7PzDfKmPwvj-SGGH27oGW68RgeX1WJvRRp68VWNHJcMjL8Yq4WA6MNAHYVAp2NgZiEsxHjPKsTivaHk2lx0ayYX0CzW57O4DnAObKLrQNbNRJM75HNfBx-A8m3ULquR-v4HveN_VvIuud0hVLrvTWqLbJj6Hrlx0u3B3yf2dI6nTTBADzToJUYdLWhj6fjXj58zDJLRZpdO303gduqEg1MKcrSL15jKWqOQOAEj27GsqXVzZVwKEarQEOcPyNnk7cfxUdhlawhVCv0dZlnBjbQKKe4zDsNmXumoquJUsdJoWRVM6ZzrJJEsiRPLS5lJzVlieBxJCQvlh2SzbmrzmFAkjU-ZtSyRKQAcXVlZIvCKUlkontmAvO77TaiOyhwzalwKT8IcC2g34dotIC8G1Znn77hOaWet81eamKGNF3lAnvfWIMD9cE9F1qZpFyKPMEEAjwLyyBvJqmwK4A_AUkBeeasZniCj9-HFp33RzL-I9qrF1yQlVMpZwt8_U0yPx0548u-qT8lNH2uEgYvPyOZy3pptgFHLasf5y29L_Bh9 |
linkProvider | Wiley-Blackwell |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB6VIgES4k0JlDZCIHFots7LSaReysKyW7pVhdqqF2Q5flSFNlntbi6c-An9jf0leJzHalGREJdoooyV2J6xPzvjbwDe-oKYSTblnpZh4EVZKs04iLSViTEmrWnq2-Ni4wM6PI72TuPTFdhpz8LU_BDdhht6hh2v0cFxQ3p7wRp6_l30LJnMLbiNGb3tguprRx6FUKfhYCaeWYrRlleIBNtd0aXZ6P6Ez0zD6DqjxU2Qs-MTXYaydi4aPIRvbS3qEJQfvWqe98TPPwge_7eaj-BBA1Ld3dqqHsOKKp7AnXHzG_4p6MMpHjjBGD2j4V5g4NHMLbXbv_51NcE4Gam23NHngbkdWeHDoWtkfwuvgcsLiUJoBQxux7KqkOWlsllEXIG2OH0Gx4NPR_2h1yRs8ERkutyL45QqrgWy3MfUjJxJLv08DyJBMiV5nhIhEyrDkJMwCDXNeMwlJaGigc-5WSs_h9WiLNQLcJE3PiJak5BHBuPIXPMMsZcf8VTQWDvwvu04Jho2c0yqccFqHuaAmXZjtt0ceNOpTmoKj5uUNpZ6f6GJSdpomjiw2ZoDMx6Iv1V4ocpqxhIfcwRQ34G12koWZSOD_wxecuBdbTbdEyT1_nh-ssvK6RmrLit8TZiZSllT-PtnstFe3wov_111E-4Oj8b7bH908OUV3KtDjzCOcR1W59NKvTaoap5vWOf5DbdFHJg |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB6VIlVIiPcjPNoIgcSh2TovJxGnssvSLbRaIYp6QLIcP1ChTVa7mwsnfgK_kV-Cx06yWlQkxCWaKGMltmfsz_H4G4DnoSBmks15oGUcBUmRSzMOIm1lZoxJa5qH9rjY0TE9OEkOT9PTDXjVnYVx_BD9Dzf0DDteo4PPpN5bkYaefRUDyyVzBa4mlORo0qMPPXcUIp2WgpkEZiVGO1ohEu31Rdcmo-szvjDtol1Ci8sQZ08nuo5k7VQ0vgmfu0q4CJRvg2ZZDsT3P_gd_7OWt-BGC1H9fWdTt2FDVXdg66jdhL8LejrH4yYYoWc0_HMMO1r4tfaHv378nGGUjFS7_uTt2NxOrPB66hs53MVr5PNKohBbAUPbsayqZH2hbA4RX6Alzu_ByfjNx-FB0KZrCERiOjxI05wqrgVy3KfUjJtZKcOyjBJBCiV5mRMhMyrjmJM4ijUteMolJbGiUci5WSnfh82qrtRD8JE1PiFak5gnBuHIUvMCkVeY8FzQVHvwsus3Jlouc0ypcc4cC3PETLsx224ePOtVZ47A4zKl7bXOX2liijaaZx7sdNbAjP_hpgqvVN0sWBZihgAaevDAGcmqbGLQn0FLHrxwVtM_QUrv0dmnfVbPv7DmosHXxIWplLWEv38mmxwOrfDo31V3YGs6GrP3k-N3j-GaizvCIMYnsLmcN-qpgVTLctu6zm9xeRtQ |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Prediagnostic+levels+of+C-peptide%2C+IGF-I%2C+IGFBP+-1%2C+-2+and+-3+and+risk+of+endometrial+cancer&rft.jtitle=International+journal+of+cancer&rft.au=LUKANOVA%2C+Annekatrin&rft.au=ZELLNIUCH-JACQUOTTE%2C+Anne&rft.au=KROGH%2C+Vittorio&rft.au=RIBOLI%2C+Elio&rft.date=2004-01-10&rft.pub=Wiley-Liss&rft.issn=0020-7136&rft.volume=108&rft.issue=2&rft.spage=262&rft.epage=268&rft_id=info:doi/10.1002%2Fijc.11544&rft.externalDBID=n%2Fa&rft.externalDocID=15441687 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0020-7136&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0020-7136&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0020-7136&client=summon |